サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1559723

エクソソームの世界市場

Exosomes

出版日
ページ情報
英文 196 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
エクソソームの世界市場
出版日: 2024年09月24日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

エクソソームの世界市場は2030年までに3億7,700万米ドルに達する見込み

2023年に1億7,840万米ドルと推定されたエクソソームの世界市場は、2030年には3億7,700万米ドルに達すると予測され、分析期間2023～2030年のCAGRは11.3%で成長すると予測されます。本レポートで分析したセグメントの1つであるがん疾患適応症は、CAGR 16.5%を記録し、分析期間終了時には9億2,160万米ドルに達すると予測されます。神経変性疾患適応症セグメントの成長率は、分析期間中CAGR 13.7%と推定されます。

米国市場は4,550万米ドルと推定、中国はCAGR10.5％で成長予測

米国のエクソソーム市場は、2023年に4,550万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGRを10.5%として、2030年までに予測市場規模6,070万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.6%と9.2%と予測されています。欧州では、ドイツがCAGR 8.3%で成長すると予測されています。

世界のエクソソーム市場- 主要動向と促進要因のまとめ

エクソソームはバイオテクノロジーと医療にどのような革命を起こしているのか？

エクソソームは、ほぼ全ての細胞タイプから分泌される微小な小胞で、バイオテクノロジーと医学において変革のツールとなっており、細胞間コミュニケーションにおいて重要な役割を果たしています。直径30～150ナノメートルのこのナノサイズの粒子は、タンパク質、脂質、核酸（RNAなど）の積荷を元の細胞から他の細胞へと運ぶ。分子情報を伝達するこのプロセスにより、エクソソームは、免疫反応、組織修復、がんなどの疾患の進行など、様々な生理学的・病理学的プロセスを制御することができます。エクソソームは、生物学的情報の天然のキャリアーとしての役割を担っているため、現在、診断用バイオマーカーや治療薬としての可能性が広く研究されています。

近年、エクソソームは病気の診断や治療に革命をもたらす可能性があるとして注目されています。遺伝子発現を制御するマイクロRNAのような分子を運び、送達するその能力は、標的ドラッグ・デリバリー・システムの理想的な候補となります。合成ドラッグデリバリーとは異なり、エクソソームは生体適合性があり、免疫反応を引き起こすことなく体内を循環することができるため、特定の組織や細胞に治療薬を送達するための魅力的なビヒクルとなっています。さらに、エクソソームは血液脳関門のような生物学的関門を通過することができ、これまで神経疾患におけるドラッグデリバリーの課題となっていました。その結果、エクソソームに基づく治療法は、がん治療、神経変性疾患、再生医療などの分野で研究されています。精密医療の未来を再構築する可能性を秘めたエクソソームは、病気の診断、モニタリング、治療に対する革新的なアプローチの最前線にいます。

なぜエクソソームは、標的治療と診断の未来と考えられているのでしょうか？

エクソソームは、標的治療を促進し、病気の早期発見のためのバイオマーカーとしてのユニークな能力により、医療分野で大きな関心を集めています。エクソソームの主な利点の一つは、由来細胞に応じて特定の細胞や組織を標的にする自然な能力です。このターゲティング能力はエクソソームに存在する表面タンパク質とレセプターに基づくもので、これにより特定の細胞タイプに認識され、吸収されます。この特性により、エクソソームは薬物、遺伝子治療、その他の治療用分子を患部細胞に直接送達するための理想的な手段となり、オフターゲット効果を最小化し、全身的副作用のリスクを軽減します。例えばがん治療では、ある種の免疫細胞に由来するエクソソームは、抗がん剤を腫瘍細胞に直接運ぶように設計することができ、健康な組織を温存しながら治療効果を向上させる可能性があります。

診断学においては、エクソソームは様々な疾患、特にがん、心血管系疾患、神経変性疾患の非侵襲的バイオマーカーとして大いに期待されています。エクソソームは血液、尿、唾液などの体液中に放出されるため、容易に採取、分析することができ、疾患に関連する分子シグネチャーを検出することができます。例えば、がん細胞は、腫瘍の存在を特定し、病気の進行を追跡し、治療に対する反応をモニターするために使用できる特定のタンパク質やRNAを含むエクソソームを放出します。エクソソームを用いたこの"リキッドバイオプシー"アプローチは、従来の組織生検よりも侵襲性が低く、病気の早期発見やより個別化された治療戦略を可能にします。さらに、エクソソームを用いた診断により、患者の体内で起こっている分子変化をリアルタイムで知ることができ、よりダイナミックで迅速なヘルスケア介入への道が開ける可能性があります。これらの進歩は、なぜエクソソームが標的治療と病気の早期発見の将来にとって不可欠なものとなる態勢を整えているのかを明確に示しています。

エクソソーム研究の医学とバイオテクノロジーにおける応用と革新の広がりとは？

エクソソーム研究の拡大する応用は、がん治療から再生医療、ワクチン開発に至るまで、医学とバイオテクノロジーのいくつかの分野におけるイノベーションを促進しています。がん研究においては、がん細胞がエクソソームを使って周囲の組織とコミュニケーションをとり、病気の広がりを促進することから、腫瘍の進行と転移におけるエクソソームの役割が研究されています。このような腫瘍由来のエクソソームを遮断して調査することにより、研究者はがん進行の分子メカニズムに関する洞察を得て、新しい治療標的を同定することができます。さらに、エクソソームに基づくデリバリーシステムは、化学療法薬や遺伝子治療薬を腫瘍部位に直接輸送し、従来のがん治療に伴う毒性を軽減するために開発されています。このアプローチは、健康な細胞へのダメージを最小限に抑えながら、がん治療の効果を高めることが期待されます。

エクソソームは、再生医療の分野でも波紋を広げています。特に間葉系幹細胞（MSC）由来のエクソソームは、組織の修復と再生を促進する能力を実証しています。これらのエクソソームは、細胞増殖、血管新生（新生血管の形成）、抗炎症反応を刺激する生理活性分子を持ち、傷害、慢性創傷、変性疾患の治療に有用です。実際、MSC由来のエクソソームは、変形性関節症、心筋梗塞、脊髄損傷などの治療法として研究されています。免疫拒絶反応や腫瘍性などの課題に直面する従来の幹細胞治療とは異なり、エクソソームを用いた治療は、治癒や組織再生に対して、より安全で的を絞ったアプローチを提供します。

エクソソームのもう一つの画期的な応用はワクチン開発です。研究者たちは、感染症に対する免疫反応を刺激するために使用できる抗原のデリバリー・ビークルとしてのエクソソームの使用を模索しています。エクソソームは免疫細胞と自然に相互作用するため、ウイルスやバクテリアの抗原を運ぶように設計することができ、生きた病原体を持ち込むことなく、身体に免疫反応を起こさせることができます。ワクチンに対するこの新しいアプローチは、特にがんやHIV、さらにはCOVID-19のような新興感染症の脅威と闘う上で、より効果的で的を絞った免疫療法を開発する可能性を秘めています。生物学的障壁を越えて分子情報を輸送するエクソソームの汎用性により、幅広い治療・診断用途の有望なプラットフォームとなり、医療分野に革命をもたらします。

エクソソーム市場の成長を促進する要因は何か？

エクソソーム市場の成長は、個別化医療に対する需要の高まり、バイオテクノロジーの進歩、病気の早期診断への注目の高まりなど、いくつかの重要な要因によってもたらされます。最も重要な促進要因の1つは、遺伝的、分子的、環境的要因に基づいて個々の患者に合わせた治療を行う精密医療への関心の高まりです。エクソソームは、特定の分子カーゴを運び、それを標的細胞に直接送達する能力を持ち、このアプローチにとって理想的なツールです。より多くの治療法が患者特異的になるにつれ、エクソソームのような洗練された送達システムのニーズは高まり続け、市場の成長に拍車をかけると思われます。がん治療、神経変性疾患、再生医療におけるエクソソームに基づく治療の応用は急速に拡大しており、これまで治療が困難であった病態に新たな希望をもたらしています。

エクソソーム市場成長のもう一つの要因は、エクソソームの単離、特性解析、操作を可能にするバイオテクノロジーの急速な進歩です。超遠心分離、マイクロ流体工学、サイズ排除クロマトグラフィーなどのエクソソーム単離のための新しい方法によって、生物学的液体からエクソソームを高純度、高収率で採取することが容易になりました。このような技術的進歩は、エクソソームに基づく診断法や治療法の開発を促進し、臨床での使用をより身近なものにしています。さらに、次世代シークエンシング（NGS）や質量分析などの分子プロファイリング技術の向上により、研究者はより高い精度でエクソソーム内容物を分析できるようになり、新規バイオマーカーや治療標的の発見につながっています。

非侵襲的診断を重視する傾向が強まっていることも、エクソソーム市場を牽引する大きな要因です。組織生検のような従来の診断法は侵襲的で、痛みを伴い、高価であるため、血液や尿のような体液から疾患バイオマーカーを検出するエクソソームを用いたリキッドバイオプシーへの関心が高まっています。このような非侵襲的診断ツールへのシフトは、早期診断が患者の転帰を改善する上で極めて重要であるがんの発見において特に重要です。ヘルスケアシステムが早期発見と予防医療を優先するにつれ、エクソソームベースの診断薬は医療現場でより大きな役割を果たすようになると予想されます。さらに、FDAやEMAなどの規制機関がエクソソームをベースとした治療法や診断法の認可を開始するにつれて、市場は急速に拡大し、製薬会社とバイオテクノロジー新興企業の両方から多額の投資が集まることになります。

結論として、エクソソーム市場は、精密医療、バイオテクノロジーの進歩、革新的な診断・治療ソリューションへのニーズの融合によって、大きく成長する態勢が整っています。がんから神経変性疾患まで、幅広い疾患の治療におけるエクソソームの可能性が調査によって明らかになりつつある中、市場はさらなる拡大と革新を遂げると思われます。エクソソームは、細胞全体に分子メッセージを伝達し、標的療法を提供するユニークな能力により、より効果的で個別化された治療と病気の早期発見への希望を提供し、次世代医療の礎となることが期待されています。

調査対象企業の例（全46件）

  • Aruna Bio
  • Avalon GloboCare Corp
  • CD Bioparticles
  • Diagenode SA
  • EVerZom
  • Evox Therapeutics
  • ExoCoBio
  • Exosome Diagnostics, Inc.
  • Kinetic River Corp.
  • Lifeasible

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP11886

Global Exosomes Market to Reach US$377.0 Million by 2030

The global market for Exosomes estimated at US$178.4 Million in the year 2023, is expected to reach US$377.0 Million by 2030, growing at a CAGR of 11.3% over the analysis period 2023-2030. Cancer Disease Indication, one of the segments analyzed in the report, is expected to record a 16.5% CAGR and reach US$921.6 Million by the end of the analysis period. Growth in the Neurodegenerative Diseases Indication segment is estimated at 13.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$45.5 Million While China is Forecast to Grow at 10.5% CAGR

The Exosomes market in the U.S. is estimated at US$45.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$60.7 Million by the year 2030 trailing a CAGR of 10.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.6% and 9.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Exosomes Market - Key Trends and Drivers Summarized

How Are Exosomes Revolutionizing Biotechnology and Medicine?

Exosomes, tiny vesicles secreted by nearly all cell types, have become a transformative tool in biotechnology and medicine, playing a critical role in intercellular communication. These nano-sized particles, ranging from 30 to 150 nanometers in diameter, carry a cargo of proteins, lipids, and nucleic acids (such as RNA) from their cell of origin to other cells. This process of transferring molecular information enables exosomes to regulate a variety of physiological and pathological processes, including immune responses, tissue repair, and the progression of diseases such as cancer. Due to their role as natural carriers of biological information, exosomes are now being studied extensively for their potential as diagnostic biomarkers and therapeutic agents.

In recent years, exosomes have gained attention for their potential to revolutionize the diagnosis and treatment of diseases. Their ability to carry and deliver molecules like microRNAs, which regulate gene expression, makes them ideal candidates for targeted drug delivery systems. Unlike synthetic drug delivery methods, exosomes are biocompatible and can circulate in the body without triggering immune responses, which makes them attractive vehicles for delivering therapeutic agents to specific tissues or cells. Furthermore, exosomes can cross biological barriers, such as the blood-brain barrier, which has historically posed a challenge for drug delivery in neurological conditions. As a result, exosome-based therapies are being explored in areas such as cancer treatment, neurodegenerative diseases, and regenerative medicine. With their potential to reshape the future of precision medicine, exosomes are at the forefront of innovative approaches to disease diagnosis, monitoring, and treatment.

Why Are Exosomes Considered the Future of Targeted Therapies and Diagnostics?

Exosomes are garnering significant interest in the medical field due to their unique ability to facilitate targeted therapies and serve as biomarkers for early disease detection. One of the key advantages of exosomes is their natural ability to target specific cells or tissues, depending on the cell of origin. This targeting ability is based on surface proteins and receptors present on the exosomes, which allows them to be recognized and absorbed by specific cell types. This property makes exosomes an ideal vehicle for delivering drugs, gene therapies, or other therapeutic molecules directly to the affected cells, minimizing off-target effects and reducing the risk of systemic side effects. In cancer therapy, for example, exosomes derived from certain immune cells can be engineered to carry anticancer drugs directly to tumor cells, potentially improving the efficacy of the treatment while sparing healthy tissue.

In diagnostics, exosomes hold great promise as non-invasive biomarkers for various diseases, particularly cancers, cardiovascular diseases, and neurodegenerative disorders. Since exosomes are released into bodily fluids such as blood, urine, and saliva, they can be easily harvested and analyzed to detect molecular signatures associated with disease. For example, cancer cells release exosomes that contain specific proteins and RNAs that can be used to identify the presence of tumors, track disease progression, and monitor the response to treatments. This "liquid biopsy" approach using exosomes offers a less invasive alternative to traditional tissue biopsies, allowing for earlier detection of diseases and more personalized treatment strategies. Furthermore, exosome-based diagnostics can potentially provide real-time insights into the molecular changes occurring in a patient’s body, paving the way for more dynamic and responsive healthcare interventions. These advancements underscore why exosomes are poised to become integral to the future of both targeted therapies and early disease detection.

What Are the Expanding Applications and Innovations in Exosome Research Across Medicine and Biotechnology?

The expanding applications of exosome research are fueling innovations in several fields of medicine and biotechnology, ranging from cancer therapy to regenerative medicine and vaccine development. In cancer research, exosomes are being explored for their role in tumor progression and metastasis, as cancer cells use exosomes to communicate with surrounding tissues and promote the spread of the disease. By intercepting and studying these tumor-derived exosomes, researchers can gain insights into the molecular mechanisms of cancer progression and identify new therapeutic targets. Additionally, exosome-based delivery systems are being developed to transport chemotherapy drugs or gene therapies directly to tumor sites, reducing the toxicity associated with traditional cancer treatments. This approach promises to enhance the effectiveness of cancer therapies while minimizing damage to healthy cells.

Exosomes are also making waves in the field of regenerative medicine. Mesenchymal stem cell (MSC)-derived exosomes, in particular, have demonstrated the ability to promote tissue repair and regeneration. These exosomes carry bioactive molecules that stimulate cell proliferation, angiogenesis (the formation of new blood vessels), and anti-inflammatory responses, making them valuable in treating injuries, chronic wounds, and degenerative diseases. In fact, MSC-derived exosomes are being investigated as a potential treatment for conditions like osteoarthritis, myocardial infarction, and spinal cord injuries. Unlike traditional stem cell therapies, which face challenges such as immune rejection and tumorigenicity, exosome-based therapies offer a safer and more targeted approach to healing and tissue regeneration.

Another groundbreaking application of exosomes is in vaccine development. Researchers are exploring the use of exosomes as delivery vehicles for antigens, which could be used to stimulate an immune response against infectious diseases. Since exosomes naturally interact with immune cells, they can be engineered to carry viral or bacterial antigens, prompting the body to produce an immune response without introducing a live pathogen. This novel approach to vaccines holds potential for developing more effective and targeted immunotherapies, especially in combating diseases like cancer, HIV, and even emerging infectious threats such as COVID-19. The versatility of exosomes in transporting molecular information across biological barriers makes them a promising platform for a wide range of therapeutic and diagnostic applications, revolutionizing the field of medicine.

What Factors Are Driving the Growth of the Exosome Market?

The growth in the exosome market is driven by several key factors, including the rising demand for personalized medicine, advancements in biotechnology, and the increasing focus on early disease diagnosis. One of the most significant drivers is the growing interest in precision medicine, where treatments are tailored to the individual patient based on their genetic, molecular, and environmental factors. Exosomes, with their ability to carry specific molecular cargo and deliver it directly to target cells, are ideal tools for this approach. As more therapies become patient-specific, the need for sophisticated delivery systems like exosomes will continue to rise, fueling growth in the market. The application of exosome-based therapies in cancer treatment, neurodegenerative diseases, and regenerative medicine is expanding rapidly, offering new hope for conditions that have been historically difficult to treat.

Another factor contributing to the growth of the exosome market is the rapid advancement of biotechnologies that enable the isolation, characterization, and manipulation of exosomes. New methods for exosome isolation, such as ultracentrifugation, microfluidics, and size exclusion chromatography, have made it easier to harvest exosomes from biological fluids with high purity and yield. These technological advancements are facilitating the development of exosome-based diagnostics and therapies, making them more accessible for clinical use. Additionally, improvements in molecular profiling techniques, such as next-generation sequencing (NGS) and mass spectrometry, are enabling researchers to analyze the contents of exosomes with greater accuracy, leading to the discovery of novel biomarkers and therapeutic targets.

The growing emphasis on non-invasive diagnostics is another major factor driving the exosome market. Traditional diagnostic methods, such as tissue biopsies, can be invasive, painful, and expensive, leading to increased interest in liquid biopsies that use exosomes to detect disease biomarkers from bodily fluids like blood or urine. This shift towards non-invasive diagnostic tools is particularly important in cancer detection, where early diagnosis is crucial for improving patient outcomes. As healthcare systems prioritize early detection and preventive care, exosome-based diagnostics are expected to play a larger role in medical practice. Furthermore, as regulatory agencies such as the FDA and EMA begin to approve exosome-based therapies and diagnostics, the market is set to expand rapidly, attracting significant investments from both pharmaceutical companies and biotech startups.

In conclusion, the exosome market is poised for significant growth, driven by the convergence of precision medicine, biotechnology advancements, and the need for innovative diagnostic and therapeutic solutions. As research into exosomes continues to reveal their potential in treating a wide range of diseases, from cancer to neurodegenerative conditions, the market will see further expansion and innovation. With their unique ability to carry molecular messages across cells and deliver targeted therapies, exosomes are set to become a cornerstone of next-generation medicine, offering hope for more effective, personalized treatments and earlier disease detection.

Select Competitors (Total 46 Featured) -

  • Aruna Bio
  • Avalon GloboCare Corp
  • CD Bioparticles
  • Diagenode SA
  • EVerZom
  • Evox Therapeutics
  • ExoCoBio
  • Exosome Diagnostics, Inc.
  • Kinetic River Corp.
  • Lifeasible

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Exosomes - Global Key Competitors Percentage Market Share in 2024 (E)
    • Global Economic Update
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Emerging Role of Exosomes in Diagnostic and Therapeutic Applications Driving Market Growth
    • Increasing Investment in Exosome-based Research for Cancer and Neurodegenerative Diseases
    • Market Trends Toward Development of Exosome-based Biomarkers
    • Consumer Demand for Non-invasive Diagnostic Options Fueling Exosome Innovations
    • Future Directions: Harnessing Exosomes for Targeted Drug Delivery
    • Impact of Nanotechnology on Exosome Engineering and Functionalization
    • Development of Exosome-based Therapeutics for Rare Diseases
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Neurodegenerative diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Neurodegenerative diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cardiovascular diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Cardiovascular diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Infectious diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for Infectious diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 10: World 7-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World 7-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World 7-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 15: World Exosomes Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Exosomes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Exosomes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: USA 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • CANADA
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Canada 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Canada 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • JAPAN
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Japan 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • CHINA
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 30: China Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: China 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 32: China Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • EUROPE
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Europe 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Europe 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Exosomes by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe 7-Year Perspective for Exosomes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • FRANCE
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 40: France Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: France 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 42: France Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: France 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • GERMANY
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Germany 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • ITALY
    • TABLE 48: Italy Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Italy 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Italy 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • UNITED KINGDOM
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 52: UK Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: UK 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 54: UK Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: UK 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Rest of Europe 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Exosomes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Asia-Pacific 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Exosomes by Application - Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Rest of World 7-Year Perspective for Exosomes by Application - Percentage Breakdown of Value Sales for Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Diagnostics and Therapeutics for the Years 2024 & 2030
    • TABLE 66: Rest of World Recent Past, Current & Future Analysis for Exosomes by Disease Indication - Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Rest of World 7-Year Perspective for Exosomes by Disease Indication - Percentage Breakdown of Value Sales for Other Disease Indications for the Years 2024 & 2030

IV. COMPETITION